Home › Funds › Rhenman & Partners Asset Management AB › BSX

Rhenman & Partners Asset Management AB position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Rhenman & Partners Asset Management AB reported holding 315,000 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$13.7M, representing 1.52% of its reported portfolio and ranking #24 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)315.00K sh
Reported value held$13.75M
Portfolio Weight1.52%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's BSX position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in BSX in Q3 2023 at 700,000 shares (US$37.0M). The position peaked in Q3 2024 at 590,000 shares, worth US$49.4M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 315,000 shares valued at US$13.7M — a reduction of -135,500 shares quarter over quarter.. Notable position changes include a 32% trim in Q1 2025 (shares rose 6% over the following quarter), a 48% increase in Q3 2025 (shares fell 2% over the following quarter), a 45% increase in Q1 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 700.00K $36.96M New
Q4 2023 750.00K $43.36M Add
Q1 2024 582.00K $39.86M Reduce
Q2 2024 595.00K $45.82M Add
Q3 2024 590.00K $49.44M Reduce
Q4 2024 444.00K $39.66M Reduce
Q1 2025 300.00K $30.26M Reduce
Q2 2025 296.00K $31.79M Reduce
Q3 2025 438.00K $42.76M Add
Q4 2025 431.21K $41.12M Reduce
Q1 2026 625.00K $39.22M Add
Q2 2026 450.50K $19.23M Reduce
Q3 2026 315.00K $13.75M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held BSX?

Rhenman & Partners Asset Management AB has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in BSX?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 315.00K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $13.75M, representing 1.52% of its reported portfolio and ranking #24.

Has Rhenman & Partners Asset Management AB been buying or selling BSX?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB reduced its position in BSX. The position peaked in Q3 2024 at 590.00K shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.